Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy and psychotic disorders. Here, the most commonly reported side effects were tiredness, diarrhea, and changes of appetite/weight. In comparison with other drugs, used for the treatment of these medical conditions, CBD has a better side effect profile. This could improve patients' compliance and adherence to treatment. CBD is often used as adjunct therapy. Therefore, more clinical research is warranted on CBD action on hepatic enzymes, drug transporters, and interactions with other drugs and to see if this mainly leads to positive or negative effects, for example, reducing the needed clobazam doses in epilepsy and therefore clobazam's side effects. Conclusion: This review also illustrates that some important toxicological parameters are yet to be studied, for example, if CBD has an effect on hormones. Additionally, more clinical trials with a greater number of participants and longer chronic CBD administration are still lacking.
Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy and psychotic disorders. Here, the most commonly reported side effects were tiredness, diarrhea, and changes of appetite/weight. In comparison with other drugs, used for the treatment of these medical conditions, CBD has a better side effect profile. This could improve patients' compliance and adherence to treatment. CBD is often used as adjunct therapy. Therefore, more clinical research is warranted on CBD action on hepatic enzymes, drug transporters, and interactions with other drugs and to see if this mainly leads to positive or negative effects, for example, reducing the needed clobazam doses in epilepsy and therefore clobazam's side effects. Conclusion: This review also illustrates that some important toxicological parameters are yet to be studied, for example, if CBD has an effect on hormones. Additionally, more clinical trials with a greater number of participants and longer chronic CBD administration are still lacking.
Entities:
Keywords:
cannabidiol; cannabinoids; medical uses; safety; side effects; toxicity
Authors: A W Zuardi; J A S Crippa; J E C Hallak; J P Pinto; M H N Chagas; G G R Rodrigues; S M Dursun; V Tumas Journal: J Psychopharmacol Date: 2008-09-18 Impact factor: 4.153
Authors: Nicholas A Jones; Andrew J Hill; Imogen Smith; Sarah A Bevan; Claire M Williams; Benjamin J Whalley; Gary J Stephens Journal: J Pharmacol Exp Ther Date: 2009-11-11 Impact factor: 4.030
Authors: Francisco J Alvarez; Hector Lafuente; M Carmen Rey-Santano; Victoria E Mielgo; Elena Gastiasoro; Miguel Rueda; Roger G Pertwee; Ana I Castillo; Julián Romero; José Martínez-Orgado Journal: Pediatr Res Date: 2008-12 Impact factor: 3.756
Authors: Sean D McAllister; Rigel T Christian; Maxx P Horowitz; Amaia Garcia; Pierre-Yves Desprez Journal: Mol Cancer Ther Date: 2007-11 Impact factor: 6.261
Authors: Paolo Fusar-Poli; José A Crippa; Sagnik Bhattacharyya; Stefan J Borgwardt; Paul Allen; Rocio Martin-Santos; Marc Seal; Simon A Surguladze; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip K McGuire Journal: Arch Gen Psychiatry Date: 2009-01
Authors: P Consroe; J Laguna; J Allender; S Snider; L Stern; R Sandyk; K Kennedy; K Schram Journal: Pharmacol Biochem Behav Date: 1991-11 Impact factor: 3.533
Authors: Rafael Guimarães Dos Santos; Flávia de Lima Osório; Rocio Martin-Santos; Antonio Waldo Zuardi; Jaime Eduardo Cecilio Hallak; José Alexandre S Crippa Journal: CNS Drugs Date: 2019-10 Impact factor: 5.749
Authors: José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-01-31 Impact factor: 5.270